Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 7/20 | 0.55 |
| ▸ | RAB9A | P51151 | 7/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.55 |
| ▸ | MAPT | P10636 | 4/20 | 0.55 |
| ▸ | HTT | P42858 | 4/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.55 |
| ▸ | LMNA | P02545 | 4/20 | 0.55 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.55 |
| ▸ | PAX8 | Q06710 | 2/20 | 0.55 |
| ▸ | XBP1 | P17861 | 3/20 | 0.46 |
| ▸ | MAPK14 | Q16539 | 6/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | NPBWR1 | P48145 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | NOS3 | P29474 | 1/20 | 0.39 |
| ▸ | NOS1 | P29475 | 1/20 | 0.39 |
| ▸ | NOS2 | P35228 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3037752 | 0.99 | NPC1 (0.53) | NPC1RAB9AALDH1A1MAPTHTT | |
| SCHEMBL13562608 | 0.88 | MAPK14 (0.41) | NPC1RAB9AALDH1A1MAPTHTT | |
| SCHEMBL3032744 | 0.85 | ALDH1A1 (0.55) | NPC1RAB9AALDH1A1MAPTHTT | |
| SCHEMBL3043247 | 0.82 | ALDH1A1 (0.51) | NPC1RAB9AALDH1A1MAPTHTT | |
| SCHEMBL18467669 | 0.80 | NPC1 (0.48) | NPC1RAB9AALDH1A1MAPTHTT | |
| SCHEMBL3028836 | 0.79 | ALDH1A1 (0.63) | NPC1RAB9AALDH1A1MAPTHTT | |
| SCHEMBL3038962 | 0.78 | SMN1; SMN2 (0.46) | NPC1RAB9AALDH1A1MAPTHTT | |
| SCHEMBL13219709 | 0.77 | CA1 (0.46) | NPC1RAB9AALDH1A1MAPTHTT | |
| SCHEMBL4191587 | 0.74 | NPC1 (0.69) | NPC1RAB9AALDH1A1MAPTHTT | |
| SCHEMBL3032746 | 0.74 | ALDH1A1 (0.56) | NPC1RAB9AALDH1A1MAPTHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9562019-B2 | Substituted pyridazines as EGFR and/or KRAS inhibitors | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2017-02-07 | — | — | US | disclosed |
| US-9562019-B2 | Substituted pyridazines as EGFR and/or KRAS inhibitors | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2017-02-07 | — | — | US | disclosed |
| EP-2518063-B1 | Pyridazinones and furan-containing compounds | SLOAN-KETTERING INST FOR CANCER RES (US) | 2017-02-01 | — | — | EP | disclosed |
| EP-2099770-B1 | PYRIDAZINONES AND FURAN-CONTAINING COMPOUNDS | SLOAN KETTERING INST CANCER (US) | 2015-06-10 | — | — | EP | disclosed |
| US-20130131062-A1 | PYRIDAZINONES AND FURAN-CONTAINING COMPOUNDS | DJABALLAH HAKIM (US) | 2013-05-23 | — | — | US | disclosed |
| US-20130131062-A1 | PYRIDAZINONES AND FURAN-CONTAINING COMPOUNDS | DJABALLAH HAKIM (US) | 2013-05-23 | — | — | US | disclosed |
| EP-2518063-A1 | Pyridazinones and furan-containing compounds | Sloan-Kettering Institute For Cancer Research (US) | 2012-10-31 | — | — | EP | disclosed |
| US-20100210649-A1 | PYRIDAZINONES AND FURAN-CONTAINING COMPOUNDS | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2010-08-19 | — | — | US | disclosed |
| US-20100210649-A1 | PYRIDAZINONES AND FURAN-CONTAINING COMPOUNDS | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2010-08-19 | — | — | US | disclosed |
| WO-2008080056-A2 | PYRIDAZINONES AND FURAN-CONTAINING COMPOUNDS | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2008-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130131062-A1 | PYRIDAZINONES AND FURAN-CONTAINING COMPOUNDS | DPYD, PDXK, TYMP | NPC1 2857/4885RAB9A 3655/4885ALDH1A1 761/4885 |
| US-20100210649-A1 | PYRIDAZINONES AND FURAN-CONTAINING COMPOUNDS | DPYD, PDXK, TYMP | NPC1 2857/4885RAB9A 3655/4885ALDH1A1 761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.